Literature DB >> 21605886

Arsenic mediated disruption of promyelocytic leukemia protein nuclear bodies induces ganciclovir susceptibility in Epstein-Barr positive epithelial cells.

Mark D Sides1, Gregory J Block, Bin Shan, Kyle C Esteves, Zhen Lin, Erik K Flemington, Joseph A Lasky.   

Abstract

Promyelocytic leukemia protein nuclear bodies (PML NBs) have been implicated in host immune response to viral infection. PML NBs are targeted for degradation during reactivation of herpes viruses, suggesting that disruption of PML NB function supports this aspect of the viral life cycle. The Epstein-Barr virus (EBV) Latent Membrane Protein 1 (LMP1) has been shown to suppress EBV reactivation. Our finding that LMP1 induces PML NB immunofluorescence intensity led to the hypothesis that LMP1 may modulate PML NBs as a means of maintaining EBV latency. Increased PML protein and morphometric changes in PML NBs were observed in EBV infected alveolar epithelial cells and nasopharyngeal carcinoma cells. Treatment with low dose arsenic trioxide disrupted PML NBs, induced expression of EBV lytic proteins, and conferred ganciclovir susceptibility. This study introduces an effective modality to induce susceptibility to ganciclovir in epithelial cells with implications for the treatment of EBV associated pathologies.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21605886      PMCID: PMC3112289          DOI: 10.1016/j.virol.2011.04.005

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  87 in total

1.  Induction of Epstein-Barr virus kinases to sensitize tumor cells to nucleoside analogues.

Authors:  S M Moore; J S Cannon; Y C Tanhehco; F M Hamzeh; R F Ambinder
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

2.  Induction of lytic Epstein-Barr virus (EBV) infection by synergistic action of rituximab and dexamethasone renders EBV-positive lymphoma cells more susceptible to ganciclovir cytotoxicity in vitro and in vivo.

Authors:  Masanori Daibata; Kentaro Bandobashi; Masayuki Kuroda; Shosuke Imai; Isao Miyoshi; Hirokuni Taguchi
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

Review 3.  The choice of prodrugs for gene directed enzyme prodrug therapy of cancer.

Authors:  T A Connors
Journal:  Gene Ther       Date:  1995-12       Impact factor: 5.250

4.  Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body.

Authors:  T R Yeager; A A Neumann; A Englezou; L I Huschtscha; J R Noble; R R Reddel
Journal:  Cancer Res       Date:  1999-09-01       Impact factor: 12.701

5.  Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus-associated lymphoma.

Authors:  S J Mentzer; J Fingeroth; J J Reilly; S P Perrine; D V Faller
Journal:  Blood Cells Mol Dis       Date:  1998-06       Impact factor: 3.039

6.  Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma.

Authors:  Elizabeth Fox; Bassem I Razzouk; Brigitte C Widemann; Shaun Xiao; Michelle O'Brien; Wendy Goodspeed; Gregory H Reaman; Susan M Blaney; Anthony J Murgo; Frank M Balis; Peter C Adamson
Journal:  Blood       Date:  2007-10-24       Impact factor: 22.113

7.  The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified.

Authors:  S M Freeman; C N Abboud; K A Whartenby; C H Packman; D S Koeplin; F L Moolten; G N Abraham
Journal:  Cancer Res       Date:  1993-11-01       Impact factor: 12.701

8.  The incidence of recurrent herpes simplex and herpes zoster infection during treatment with arsenic trioxide.

Authors:  Keyvan Nouri; Carlos A Ricotti; Navid Bouzari; Halland Chen; Eugene Ahn; Ardalan Bach
Journal:  J Drugs Dermatol       Date:  2006-02       Impact factor: 2.114

9.  Epstein-Barr-virus-associated medullary carcinomas with lymphoid infiltration of the stomach.

Authors:  Y Takano; Y Kato; H Sugano
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

10.  Herpes zoster during treatment with arsenic trioxide.

Authors:  T Tanvetyanon; S Nand
Journal:  Ann Hematol       Date:  2003-10-08       Impact factor: 3.673

View more
  17 in total

1.  Functions of the Epstein-Barr virus EBNA1 protein in viral reactivation and lytic infection.

Authors:  Nirojini Sivachandran; Xueqi Wang; Lori Frappier
Journal:  J Virol       Date:  2012-04-04       Impact factor: 5.103

2.  Epstein-Barr virus latent membrane protein 1 (LMP1) C-terminal-activating region 3 contributes to LMP1-mediated cellular migration via its interaction with Ubc9.

Authors:  Gretchen L Bentz; Christopher B Whitehurst; Joseph S Pagano
Journal:  J Virol       Date:  2011-07-27       Impact factor: 5.103

3.  Assembly of Epstein-Barr Virus Capsid in Promyelocytic Leukemia Nuclear Bodies.

Authors:  Wen-Hung Wang; Chung-Wen Kuo; Li-Kwan Chang; Chen-Chia Hung; Tzu-Hsuan Chang; Shih-Tung Liu
Journal:  J Virol       Date:  2015-06-17       Impact factor: 5.103

4.  EBV-related lymphomas: new approaches to treatment.

Authors:  Jennifer A Kanakry; Richard F Ambinder
Journal:  Curr Treat Options Oncol       Date:  2013-06

5.  SUMO binding by the Epstein-Barr virus protein kinase BGLF4 is crucial for BGLF4 function.

Authors:  Renfeng Li; Leyao Wang; Gangling Liao; Catherine M Guzzo; Michael J Matunis; Heng Zhu; S Diane Hayward
Journal:  J Virol       Date:  2012-03-07       Impact factor: 5.103

6.  LMP1-Induced Sumoylation Influences the Maintenance of Epstein-Barr Virus Latency through KAP1.

Authors:  Gretchen L Bentz; Charles Randall Moss; Christopher B Whitehurst; Cary A Moody; Joseph S Pagano
Journal:  J Virol       Date:  2015-05-06       Impact factor: 5.103

7.  Arsenic trioxide stabilizes accumulations of adeno-associated virus virions at the perinuclear region, increasing transduction in vitro and in vivo.

Authors:  Angela M Mitchell; Chengwen Li; R Jude Samulski
Journal:  J Virol       Date:  2013-02-13       Impact factor: 5.103

8.  Arsenicals, the Integrated Stress Response, and Epstein-Barr Virus Lytic Gene Expression.

Authors:  Jaeyeun Lee; Jennifer Stone; Prashant Desai; John G Kosowicz; Jun O Liu; Richard F Ambinder
Journal:  Viruses       Date:  2021-04-30       Impact factor: 5.048

Review 9.  Contributions of Epstein-Barr nuclear antigen 1 (EBNA1) to cell immortalization and survival.

Authors:  Lori Frappier
Journal:  Viruses       Date:  2012-09-13       Impact factor: 5.818

10.  Co-treatment with arsenic trioxide and ganciclovir reduces tumor volume in a murine xenograft model of nasopharyngeal carcinoma.

Authors:  Mark D Sides; Meredith L Sosulski; Fayong Luo; Zhen Lin; Erik K Flemington; Joseph A Lasky
Journal:  Virol J       Date:  2013-05-16       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.